The 10 new flu-related deaths in children bring the season's total to 226, the most since 2009-10.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
The CDC says it does not anticipate posting any more updates on US respiratory disease activity this season.
Median cumulative state rates ranged from 23 (Alaska) to 249 (New York) per 100,000 people.
The CDC says it's now classifying the flu season as high severity for all age-groups for the first time since the 2017-18 season.
Test positivity topped 30%, with steady rises in emergency department visits and hospitalizations.
Median hospital stay was longer in the RSV group than in flu patients.
Oseltamivir recipients had an 18% lower risk of 30-day mortality.
The highest rates of influenza A/B (21%), influenza A (17%), and influenza B (20%) were observed in Asia and Europe.
Sixteen more flu deaths were reported in children, with virus activity at high or very high flu levels across much of the nation.
By 180 days, the COVID-19 death rate reached 3.1% in the 2022-23 season and 2.9% in the 2023-24 season.
Both oseltamivir and baloxivir have a role in the treatment of flu, the healthcare professionals say.
